The estimated Net Worth of Kimberlee C Drapkin is at least $2.98 Million dollars as of 9 January 2023. Ms. Drapkin owns over 14,096 units of Jounce Therapeutics Inc stock worth over $124,114 and over the last 7 years she sold JNCE stock worth over $827,367. In addition, she makes $2,032,250 as Chief Financial Officer und Treasurer at Jounce Therapeutics Inc.
Kimberlee has made over 11 trades of the Jounce Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 14,096 units of JNCE stock worth $15,647 on 9 January 2023.
The largest trade she's ever made was selling 30,000 units of Jounce Therapeutics Inc stock on 20 January 2021 worth over $340,800. On average, Kimberlee trades about 5,016 units every 89 days since 2018. As of 9 January 2023 she still owns at least 66,018 units of Jounce Therapeutics Inc stock.
You can see the complete history of Ms. Drapkin stock trades at the bottom of the page.
Kimberlee Cobleigh Drapkin CPA serves as Chief Financial Officer, Treasurer of the Company. From 2009 to August 2015, Ms. Drapkin was the owner of KCD Financial LLC, through which she served as our interim chief financial officer from 2012 to August 2015, and consulted for numerous biotechnology companies. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant and holds a B.S. in accounting from Babson College.
As the Chief Financial Officer und Treasurer of Jounce Therapeutics Inc, the total compensation of Kimberlee Drapkin at Jounce Therapeutics Inc is $2,032,250. There are no executives at Jounce Therapeutics Inc getting paid more.
Kimberlee Drapkin is 52, she's been the Chief Financial Officer und Treasurer of Jounce Therapeutics Inc since 2015. There are 14 older and 1 younger executives at Jounce Therapeutics Inc. The oldest executive at Jounce Therapeutics Inc is Dr. Louis M. Weiner M.D., 69, who is the Founder.
Kimberlee's mailing address filed with the SEC is C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca... und Rock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Jounce Therapeutics Inc executives and other stock owners filed with the SEC include: